Literature DB >> 19290502

Application of disposable bag bioreactors in tissue engineering and for the production of therapeutic agents.

R Eibl1, D Eibl.   

Abstract

In order to increase process efficiency, many pharmaceutical and biotechnology companies have introduced disposable bag technology over the last 10 years. Because this technology also greatly reduces the risk of cross-contamination, disposable bags are preferred in applications in which an absolute or improved process safety is a necessity, namely the production of functional tissue for implantation (tissue engineering), the production of human cells for the treatment of cancer and immune system diseases (cellular therapy), the production of viruses for gene therapies, the production of therapeutic proteins, and veterinary as well as human vaccines.Bioreactors with a pre-sterile cultivation bag made of plastic material are currently used in both development and manufacturing processes primarily operating with animal and human cells at small- and middle-volume scale. Because of their scalability, hydrodynamic expertise and the convincing results of oxygen transport efficiency studies, wave-mixed bioreactors are the most used, together with stirred bag bioreactors and static bags, which have the longest tradition.Starting with a general overview of disposable bag bioreactors and their main applications, this chapter summarizes the working principles and engineering aspects of bag bioreactors suitable for cell expansion, formation of functional tissue and production of therapeutic agents. Furthermore, results from selected cultivation studies are presented and discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19290502     DOI: 10.1007/978-3-540-69357-4_8

Source DB:  PubMed          Journal:  Adv Biochem Eng Biotechnol        ISSN: 0724-6145            Impact factor:   2.635


  5 in total

1.  High yield of human monoclonal antibody produced by stably transfected Drosophila schneider 2 cells in perfusion culture using wave bioreactor.

Authors:  Lulan Wang; Hongxing Hu; Jianjun Yang; Feng Wang; Christian Kaisermayer; Paul Zhou
Journal:  Mol Biotechnol       Date:  2012-10       Impact factor: 2.695

2.  High cell density cultivation and recombinant protein production with Escherichia coli in a rocking-motion-type bioreactor.

Authors:  Julia Glazyrina; Eva-Maria Materne; Thomas Dreher; Dirk Storm; Stefan Junne; Thorsten Adams; Gerhard Greller; Peter Neubauer
Journal:  Microb Cell Fact       Date:  2010-05-30       Impact factor: 5.328

3.  Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor.

Authors:  Robert P T Somerville; Laura Devillier; Maria R Parkhurst; Steven A Rosenberg; Mark E Dudley
Journal:  J Transl Med       Date:  2012-04-04       Impact factor: 5.531

4.  Single use bioreactors for the clinical production of monoclonal antibodies - a study to analyze the performance of a CHO cell line and the quality of the produced monoclonal antibody.

Authors:  Sonja Diekmann; Constanze Dürr; Alexander Herrmann; Ingo Lindner; Daniela Jozic
Journal:  BMC Proc       Date:  2011-11-22

5.  Very high density of CHO cells in perfusion by ATF or TFF in WAVE bioreactor™. Part I. Effect of the cell density on the process.

Authors:  Marie-Françoise Clincke; Carin Mölleryd; Ye Zhang; Eva Lindskog; Kieron Walsh; Véronique Chotteau
Journal:  Biotechnol Prog       Date:  2013-05-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.